ASTRO 2022 | The impact of time-to-treatment on SBRT outcomes

Kevin Stephans, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of the length of time from diagnosis to treatment on the outcome of stereotactic body radiation therapy (SBRT) for patients with non-small cell lung cancer (NSCLC). It was found that time-to-treatment did not affect SBRT outcomes, however Dr Stephans notes that there may be bias. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.